After Aduhelm fallout, FDA veteran Woodcock out of running for commish job: report Bristol Myers keeps the perioperative ball rolling with Opdivo nod in postsurgery bladder cancer Nursing home groups decry mandate push by CMS for staff to get COVID-19 vaccine J&J CEO Gorsky to step aside, handing reins of world's largest pharma to COVID-19 navigator Duato Physician pay remained stagnant while productivity slumped in 2020, new survey finds COVID testing drought leads LumiraDx to cut $2B off SPAC deal value Cerner taps Google, Geisinger vet Feinberg as new CEO Moderna's ‘Make it Yours’ vaccine campaign taps local partners like Seattle Seahawks, Boston Red Sox Nanox faces regulatory roadblock in FDA review of multisource digital X-ray bed Insurers take cue from providers, begin requiring vaccines for employees COVID-19 tracker: Regeneron, Roche antibody nabs UK nod; AstraZeneca tees up cocktail filing after trial win Featured Story | By Ben Adams Janet Woodcock, M.D., has spent more than three decades at the FDA, but her time running the agency as its interim leader is looking less likely to materialize into a full-time gig. read more |
| |
|---|
|
Top Stories By Angus Liu In the next frontier of immuno-oncology competition focusing on treatment around surgery, Bristol Myers Squibb has snatched another U.S. license for Opdivo—this time in bladder cancer. read more By Robert King Nursing home groups blasted a plan by CMS to require staff to get vaccinated, arguing such a mandate will make workforce shortages worse. read more By Angus Liu Johnson & Johnson is switching captain to lead the world’s largest pharma company by 2020 revenue. Nine-year CEO Alex Gorsky will hand the helm to vice chairman of executive committee and leader of its COVID-19 response group, Joaquin Duato, early 2022. read more By Anastassia Gliadkovskaya According to the latest AMGA medical group compensation and productivity survey, increases in compensation were modest, while there was a significant negative impact on productivity as a result of the COVID-19 pandemic. read more By Conor Hale Drops in demand for COVID-19 screening have led test maker LumiraDx to dramatically cut back its plans for going public, slashing 40% off the value of a planned reverse merger. read more By Heather Landi David Feinberg, who spent the past two years at Google leading the tech giant's health efforts, is moving over to lead Cerner after a three-month CEO search. read more By Beth Snyder Bulik From home improvement shows to Louis Vuitton fashion, “Make it Yours” slogans have encouraged people to adopt their own style. Now, Moderna is using the tagline to encourage COVID-19 vaccinations. read more By Andrea Park According to forms filed with the SEC this week, the FDA has temporarily paused its review of the multisource Nanox.ARC while it waits for Nanox to provide additional information about the X-ray bed. read more By Paige Minemyer Major insurers are beginning to follow in the footsteps of big-name providers in mandating COVID-19 vaccines for their workforces. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Regeneron's Roche-partnered monoclonal antibody, dubbed REGEN-COV in the U.S., has scored a nod from the U.K.'s drug regulator to treat and prevent COVID-19. AstraZeneca scored a win with promising late-stage trial data for its long-acting antibody cocktail. Plus more. read more |
